Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomea Fusion Inc (NQ: BMEA )

13.76 +0.32 (+2.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 591,597
Open 13.55
Bid (Size) 5.510 (2)
Ask (Size) 19.99 (2)
Prev. Close 13.44
Today's Range 13.29 - 13.94
52wk Range 6.040 - 38.84
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer
From Biomea Fusion, Inc.
Via GlobeNewswire

Performance

YTD
+62.26%
+62.26%
1 Month
-16.91%
-16.91%
3 Month
-37.31%
-37.31%
6 Month
-55.63%
-55.63%
1 Year
+44.69%
+44.69%

More News

Read More
Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
14 Analysts Have This to Say About Biomea Fusion
Via Benzinga
Why Biomea Fusion Stock Is Falling Today?
Via Benzinga
What 18 Analyst Ratings Have To Say About Biomea Fusion
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
Via Benzinga
BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
From Biomea Fusion, Inc.
Via GlobeNewswire
Analyst Ratings for Biomea Fusion
Via Benzinga
Recap: Biomea Fusion Q1 Earnings
Via Benzinga
Analyst Ratings for Biomea Fusion
Via Benzinga
Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Are (More) Big Gains Ahead for This Small Cap Biotech Stock?
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Dow Surges Over 50 Points; Avalo Therapeutics Shares Plummet
Via Benzinga
Crude Oil Rises; Carnival Shares Drop After Q2 Results
Via Benzinga
Biomea Fusion Stock Is Trading Higher Today - Here's Why
Via Benzinga
Why Carnival Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023
From Biomea Fusion, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2023
Via Benzinga
Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
From Biomea Fusion, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.